CSChristy Santhosh

1. Article · Aug 19, 2026 · By Christy Santhosh and Shashwat Chauhan

   Moderna shares double as cancer vaccine data rekindles investor hopes (opens the original)

   Excerpt · Positive tone · English

   Read excerpt

   By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer ‌therapy developed with Merck sent investors piling into the stock. The therapy is central to Moderna's ‌efforts to prove that its mRNA technology can succeed beyond its COVID-19 vaccine franchise and infectious disease shots, as it seeks to ​build a more durable revenue base. The c

   Feedback

2. Article · Jul 31, 2026 · By Christy Santhosh

   Replimune surges after FDA advisers back skin cancer drug (opens the original)

   Excerpt · English

   Read excerpt

   July 31 (Reuters) - Shares of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's ‌panel of outside advisers voted to back trial results for ‌its drug for a type of skin cancer. Late on Thursday, the panel voted 10 ​to 3 in favor of the drug, RP1, concluding that trial data showed patient benefit, despite concerns raised earlier in the week by FDA staff reviewers that trial design flaws made it unclear whether tumor shrinkage resulted ‌from RP1 or anothe

   Feedback

Last 90 days. Choose a month to open its work.

Named in the text we hold. One piece can cover several.

• Bristol Myers Squibb1 piece
• Drug Administration1 piece